



European Journal Osteopathy & Clinical Related Research



ORIGINAL ARTICLE

Influence of Lung Compression Technique on Spirometric Values in Smokers : A Pilot Study

Baño-Alcaráz A * ^a (PT,DO), Peinado-Asensio M ^a (PT,DO)

a. Madrid Osteopathic School. Madrid. Spain.

Received 26 January 2012 ; accepted 30 March 2012

ABSTRACT

Key Words:

Lung;
Osteopathic Medicine;
Smoking;
Spirometry.

Introduction: The essential function of the respiratory system is to supply oxygen to the blood, which requires an adequate respiratory mechanics. The elastic forces increase lung retraction during inhalation and decrease proportionally to the exhalation. There is evidence that smokers experience a drop in Forced Expiratory Volume in 1 second (FEV1) of about 50 mL/year.

Objectives: To evaluate the influence of the Lung Compression Technique (LCT) on Spirometric Values (SV) in smokers.

Material and Methods: A randomized pilot study was conducted. We applied a LCT in forty-one (n=41) smokers, which were randomly distributed into two groups (experimental: n=24; control: n=17). All of them underwent spirometry before and after the intervention. They were previously surveyed about their smoking habits and the presence or absence of comorbidities. We analyzed the changes in the following spirometric values: Forced Vital Capacity (FVC), Forced Expiratory Volume (FEV1), Peak Expiratory Flow (PEF), and Forced Expiratory Flow 25–75% (FEF2575). Spirometry was performed according to the rules of the American Thoracic Society (ATS) and Spanish Society of Pneumology and Thoracic Surgery (SEPAR).

Results: The results indicate that there are significant variations in PEF (p=0.008) and FEF2575 (p=0.005) in the experimental group versus the control group after application of the LCT. We found an increase statistically significant in PEF and FEF2575 in the experimental group. No changes were found in FVC (p=0.634) and FEV1 (p=0.058) between study groups.

Conclusions: The LCT could be helpful for improving respiratory mechanics in smokers, increasing spirometric variables as PEF and FEF25-75%.

* Corresponding author: email: aitor_ft@hotmail.com (Aitor Baño) - ISSN on line: 2173-9242

© 2012 – Eur J Ost Clin Rel Res - All rights reserved - www.europeanjournalosteopathy.com - info@europeanjournalosteopathy.com

INTRODUCTION

The essential function of the respiratory system is to supply oxygen (O₂) to the blood, which will be transported to the tissues, as well as to remove carbon dioxide (CO₂) from the blood to the atmosphere. This function needs proper respiratory mechanics ¹.

The elasticity of the respiratory system is a decisive force in respiratory mechanics, which depends on the combined elasticity of the lung and the chest ¹⁻⁵.

The elastic forces of retraction of the lung increase during inhalation due to increased surface tension and to stretching of the elastic fibers of the lung. These forces decrease proportionally during exhalation ¹.

Smoking is associated with decreased lung function⁶⁻⁹, particularly with an important annual decline in FEV1 (40 ml compared to 25 ml in nonsmokers) ¹⁰.

Reduced lung function, measured as Flow Expiratory Volume in one second (FEV1), is associated with increased mortality derived from respiratory problems ¹¹.

Studies of lung function monitoring have shown that nonsmokers from 30 years old, exempt from any other respiratory disease, experience a significant decline in FEV1 of 30 to 35 mL/year¹², related to the natural aging process of the lung.

This drop is slightly higher in smokers, about 50 mL/year ^{13,14}. In fact, smoking is a major risk factor for developing Chronic Obstructive Pulmonary Disease (COPD)^{12, 14-27}.

From 40-50 years onwards, the prevalence of developing COPD increases every year and more in smokers ²⁸. In this sense, a fully effective respiratory cycle can be achieved by increasing the mobility of the ribcage and thoracic spine ²⁹.

MATERIAL AND METHODS

Design

The study was a controlled, randomized, double-blind clinical trial (patients and assessors were blinded).

Study Population

We included in our research forty-one (n=41) patients, who were divided into two groups: experimental group (EG) and control group (CG). The EG was composed of twenty-four (n=24) patients (11 men and 13 women) with a mean age of 32.79 ± 8.4 years, whereas in the CG were seventeen (n=17) patients (8 men and 9 women) with a mean age of 32.76 ± 10.7 years.

Randomization

The randomization was performed by random number tables.

Study Protocol

Patients were surveyed about their smoking habits and recent presence of associated diseases.

They were informed about the study and were given the informed consent form that must be signed prior to treatment.

Afterwards, each patient was randomly distributed in one group (EG or CG). Both groups underwent spirometry before the intervention (pre-intervention).

Then we applied the Lung Compression Technique (LCT) to the EG, but the CG did not receive any intervention. Immediately after applying the LCT, we performed again other spirometry in both groups (post-intervention).

Selection Criteria

Patients included in the study met the inclusion criteria and did not meet any exclusion criteria (Table 1).

Inclusion criteria were the following:

1. - The patient must sign the informed consent form.

The confidentiality of personal data was respected in accordance with the current spanish legislation (Law 15/1999 Protection of Personal Data ³⁰). All necessary data, both personal and health data were

essential data for the study. Likewise, we inform participants that their personal information not be disclosed to anyone outside the investigation.

2. - Patients smoking for more than 2 years.
3. - Patients who smoke more than 10 cigarettes/day³¹.
4. - Age between 18 and 50 years ^{28, 32}.

Intervention in Experimental Group

Patients of the EG were submitted to the LCT ^{33, 34}. This technique aims to provoke a therapeutic elastic rebound in the lung, because manual compression which is exerted on the patient in the expiratory phase of respiration, in addition to the sudden decompression is performed in the inspiratory phase of respiration.

The patient remains in the supine position with hip and knee flexion, so that the feet soles are flat on the table. The therapist is placed beside the table, placing a hand behind the patient's thorax and the other hand is resting on the anterior part of the hemithorax (figure 1).

The technique consisted of applying compression to the chest during the expiratory phase, while maintaining this compression at the beginning of the inspiratory phase and dropping abruptly at the end of the inspiratory phase. We performed a rhythmic pumping technique synchronized with the patient breathing in both hemithorax (bilaterally).

Intervention in Control Group

Patients of the CG were placed in the same position as patients of EG. The therapist performed the same contacts and held such position during 3 breaths, but exerting no compression at all.

Spirometric Variables

Patients of both groups (EG and CG) underwent three pre-intervention spirometry tests and three post-intervention spirometry tests, and we used the mean of these measurements.

1. - Lung Cancer
2. - Hemothorax
3. - Acute infections
4. - Acute respiratory failure
5. - Myocardial infarction within the last month
6. - Rib fractures
7. - Recent cardiac crisis
8. - Recent surgery (eye, ear, chest and abdomen)
9. - Pregnancy
10. - Poor health status, cardiovascular instability, fever, nausea, vomiting
11. - Pneumothorax
12. - Active tuberculosis
13. - Hemoptysis
14. - Aneurysms
15. - Tracheotomies

Table 1. Exclusion Criteria



Figure 1. Lung Compression Technique (LCT)

To perform spirometry we used a Datospir 120A spirometer (Sibelmed, Barcelona, Spain), previously calibrated following the manufacturer's recommendations and standards for spirometric testing, according to the American Thoracic Society (ATS) ³⁵ and the Spanish Society of Pneumology and Thoracic Surgery (SEPAR).

Spirometric variables considered were:

- FVC (Forced Vital Capacity): The maximum volume of air exhaled after a maximal inspiration, expressed in liters (L).
- FEV1 (Forced Expiratory Volume in one second): Volume of air exhaled during the first second of FVC in liters (L).
- PEF (Peak Expiratory Flow): Peak flow reached a maximum effort from a position of maximal inspiration, expressed in liters/second (L/s).
- FEF25-75: (Forced Expiratory Flow 25-75 %) Forced Expiratory Flow average measured during the middle half of FVC, expressed in L/s.

Statistical Analysis

Statistical analysis was performed using the software "SPSS for Windows" version 15.0.

The normality of variables was established using the Kolmogorov-Smirnov test and graphical methods. When we observed a non-normal distribution we applied nonparametric tests (Mann-Whitney).

In the case of normal distribution we used parametric tests (Student t-test). We applied the chi-square tests χ^2 for analysis of dichotomous variables (table 2).

We established a significance level of $p < 0.05$, according to international standards for biomedical research ^{36, 37}.

RESULTS

Our results indicated a clear statistical difference in PEF ($p=0.008$) and FEF2575 ($p=0.005$) between the CG and EG.

We found an increase statistically significant in PEF and FEF2575 in the experimental group. No changes were found in FVC ($p=0.634$) and FEV1 ($p=0.058$) between study groups.

Although the FEV1 was statistically not significant ($p=0.058$), we observed a trend to statistical significance. Likewise, no significant variations were observed in FVC (table 3).

DISCUSSION

Some authors observed that the use of different techniques in smokers produced changes in spirometric parameters.

According to Oscoz³¹ (2005) the application of techniques on the diaphragm resulted in the modification of some spirometric values, such as FEV1 or PEF.

Ramos and Cataneo ³⁸ (2007) reported that the application of exercise before surgery in smokers exerted a positive effect on PEF.

On the other hand, treatment with Global Postural Re-education in the anterior muscle chain, applied during 8 weeks to healthy subjects, has modified pulmonary pressures in thoracic expansion and abdominal mobility ³⁹.

The tension and relaxation of viscoelastic elements of the lung depend on time, so the peak flow immediately after stretching the lungs is higher than after a pause with the lungs at total capacity ^{40,41}.

Therefore, we may interpret that LCT can temporarily influence on the elastic properties of the lung, thereby improving some spirometric parameters immediately after the LCT.

Such parameters coincide with those most affected in smokers, indicating that the LCT would be considered as a useful procedure in the rehabilitation of lung pathology associated to smoking.

VARIABLES	GROUP		p-value
	EG n= 24	CG n= 17	
SEX (man; woman)	m: 11(45,8%) w: 13(54,2%)	m: 8(47%) w: 9(53%)	0,938
AGE (years)	32,79(8,44)	32,76(10,72)	0,993
Pre_FVC (liters)	4,30(1,06)	4,05(0,92)	0,560
Pre_FEV1 (liters)	3,31(0,75)	3,31(0,85)	0,968
Pre_PEF (liters/second)	6,77(1,74)	6,86(2,34)	0,771
Pre_FEF 2575 (liters/second)	3,17(0,88)	3,40(1,32)	0,515

Table 2. Preintervention Values

Data are expressed as mean \pm (SD) standard deviation; n: counting number; age in years; m: man; w:woman; FVC: Forced Vital Capacity (liters); FEV1: Forced Expiratory Volume in 1 second (liters); PEF: Peak Expiratory Flow (liters/second); FEF25-75%: Forced Expiratory Flow 25–75% (liters/second).

VARIABLES	GROUP		p-value
	EG	CG	
Dif_FVC (liters)	0,15(0,56)	0,22(0,45)	0,634
Dif_FEV1 (liters)	0,13(0,37)	0,00(0,31)	0,058
Dif_PEF (liters/second)	0,08(0,87)	-0,71(0,95)	0,008 *
Dif_FEF2575 (liters/second)	0,03(0,36)	-0,36(0,34)	0,005 *

Table 3. Intergroup Comparative Pre/Post Intervention Values

Parametric Data are expressed as mean \pm (SD) standard deviation; Non-Parametric Data are expressed as median \pm (IR) interquartil range; Dif_FVC: Differences in Forced Vital Capacity (liters); Dif_FEV1: Differences in Forced Expiratory Volume in 1 second (liters); Dif_PEF: Differences in Peak Expiratory Flow (liters/second); Dif_FEF25-75%: Differences in Forced Expiratory Flow 25–75% (liters/second).The statistically significant differences were expressed as *p<0.05.

We believe that the obtained results are interesting, but we must be aware that some variables, such as PEF or FEF25-75%, are dependent on the effort ^{42, 43}, so that their values (especially the PEF) does not indicate the quality of the spirometry.

On the other hand, we did not control the patient's bronchial hyperreactivity. There is evidence of a direct relationship between PEF and bronchial hyperresponsiveness ^{44, 45} in patients with asthma and COPD ⁴⁶⁻⁴⁹.

According to other authors ^{31,38,39} we can state that the use of Osteopathy Manipulative Treatment (OMT) to treat respiratory problems is beneficial, for both chest mobility problems and chain retraction muscle. Additionally, this technique might also benefit patients with visceral problems.

Finally, it would be of interest in further studies of research to analyzed the results obtained by combining other treatment techniques that have shown effective results (Oscos ³¹, Ramos and Cataneo³⁸, Moreno ³⁹).

Study Limitations

This study is limited by several aspects, including sample size, which should be increased in future studies.

In addition, a study should be conducted to determine the duration of the effect of the LCT, thereby assessing their practical applications.

CONCLUSIONS

The lung compression technique produces statistically significant increases in spirometric PEF and FEF25-75. By contrast, this technique does not modify FVC or FEV1 in lung.

ETHIC RULES

This study meets the ethical standards established in the Declaration of Helsinki ⁵⁰, and subsequent revisions.

CONFLICT OF INTEREST

The authors of the manuscript declare no conflict of interest.

ACKNOWLEDGEMENTS

We would like to thank the patients who participated in our research and all collaborators.

REFERENCES

1. González Pérez-Yarza E, Aldasoro Ruiz A, Korta Murua J, Mintegui Aranburu J, Sardón Prado O., editor. *La Función Pulmonar en el Niño. Principios y Aplicaciones*. Madrid: Ergon; 2007.
2. Chernick V, West JB., editor. *The functional basis of Respiratory Disease*, en *Kendig's Disorders of the Respiratory tract in children*. 7ª ed: Saunders-Elsevier; 2006.
3. López-Herce J, Ruipérez M, García C, García E., editor. *Fisiología de la respiración. Tratado de Neumología Infantil*. Madrid Ergon; 2003.
4. Di Fiore J, Chatburn RL, Martin RJ., editor. *Respiratory function in infants*. en: *Cherink-Mellis Basic Mechanisms of pediatric Respiratory Disease*. 2ª ed: Hamilton: BC Decker Inc.; 2002.
5. Taussig L, Helms PJ, editor. *Introduction. Infant Respiratory Function Testing*. New York: Wiley-Liss; 1996.
6. Langhammer A, Johnsen R, Gulsvik A, Holmen TL, Bjerner L. Sex differences in lung vulnerability to tobacco smoking. *Eur Respir J*. 2003;21:1017-23.
7. Pelkonen M, Notkola I, Tukiainen H, Tervahauta M, Tuomilehto J, Nissinen A. Smoking cessation, decline in pulmonary function and total mortality: a 30 year follow up study among the Finnish cohorts of the Seven Countries Study. *Torax*. 2001;56:703-7.
8. Vollmer W. Race and Gender Differences in the Effects of smoking of Lung Function. *CHEST*. 2000;117:764-74.
9. Downs S, Brändli O, Zellweger JP, Schindler C, Künzli N, Gerbase M, Burdet L, Bettschart R, Zemp E, Frey M, Keller R, Tschopp JM, Leuenberger P, Ackermann-Liebrich U and the SAPALDIA team. Accelerated decline in lung function in smoking women with airway obstruction: SAPALDIA 2 cohort study. *Respir Res*. 2005;6:12-21.
10. Pauwels R, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. *NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary*. *Am J Respir Crit Care*. 2001;163:1256-76.

11. Stavem K. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. *Eur Respir J*. 2005;25:618-25.
12. Gutierrez M. EPOC: Propuesta de manejo simple del paciente estable. *Rev Chil Enf Respir*. 2002;18:182-8.
13. Farreras R. Tratado de Medicina Interna. 2000 [cited.
14. Morgan M, Britton JR. Chronic obstructive pulmonary disease • 8: Non-pharmacological management of COPD. *Thorax*. 2008;58:453-8.
15. McDonald C. Shortness of breath. Is it chronic obstructive pulmonary disease? *AFP*. 2005;34 n°7:541-4.
16. Stratelis G, Mölsted S, Jakobsson P, Zetterström O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD'. *Scand J Prim Health Care*. 2006;24:3:133-9.
17. Eisner M. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease *Environ Health*. 2005;4:7-14.
18. Shahab L, Jarvis MJ, Britton J, West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. *Thorax*. 2006;61:1043-8.
19. Minakata Y. Prevalence of COPD in Primary Care Clinics: Correlation with Non-Respiratory Diseases. *Intern Med*. 2007;77-82.
20. Craig B, Kraus CK, Chewning BA, Davis JE. Quality of care for older adults with chronic obstructive pulmonary disease and asthma based on comparisons to practice guidelines and smoking status. *Biomed Central Health Services Research*. 8:144-52.
21. Willemse B, Postma DS, Timens W, Ten Hacken NHT. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. *Eur Respir J*. [Review]. 2004;23:464-76.
22. Bohadana A, Nilsson F, Martinet Y. Detecting Airflow Obstruction in Smoking Cessation Trials: A Rationale for Routine Spirometry. *CHEST*. 2005;128:1252-9.
23. Mapel D, Picchi M, Hurley J, Frost F, Petersen H, Mapel V, Coultas D. Utilization in COPD : Patient Characteristics and Diagnostic Evaluation. *CHEST*. 2000;117:346- 55.
24. Anto JM V, Vestboz, Sunyer. Epidemiology of chronic obstructive pulmonary disease. *European Respiratory journal*. 2001;17:13.
25. Un nuevo fármaco aleja del humo a los enfermos de pulmón. *Salud 21 de la Región de Murcia*. 2010.
26. Tønnesen P, Mikkelsen KL. Smoking cessation with four nicotine replacement regimes in a lung clinic. *Eur Respir J*. 2000;16:717-22.
27. Higenbottam T. Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. *Proc Am Thorac Soc*. 2005;2:12-9.
28. Lundbäck B, Gulsvik A, Albersz M, Bakke , Rönmark E, van den Boomz G, Brøgger J, Larsson LG, Welle I, van Weelz C, Omenaas E. Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly. *Eur Respir J*. 2003;21:3-9.
29. Guiney P, Chou R, Vianna A, Lovenheim J. Effects of Osteopathic Manipulative Treatment on Pediatric Patients With Asthma: A Randomized controlled Trial. *JAOA*. 2005;105.num 1:7-13.
30. Ley Orgánica 15/1999, de 13 de diciembre, de Protección de Datos de Carácter Personal.: B.O.E num. 298; 1999.
31. Oscoz G. La influencia de la Técnica de Stretching de la parte anterior del diafragma en los valores espirométricos en fumadores: Tesis para la obtención del D.O. EOM; 2005.
32. Ley del tabaco, Ley 28/2005, de 26 de diciembre, . (2005).
33. Ricard F, editor. Tratado de Osteopatía Visceral y Medicina Interna. Tomo I Sistema Cardiorrespiratorio: Editorial Panamericana; 2008.
34. EOM. Material Didáctico 5º Nivel. In press 2006.
35. Miller MR. Standardisation of spirometry. *Eur Respir J*. 2005;2005:319- 38.
36. Ruiz M, editor. Epidemiología Clínica. Investigación clínica aplicada.: Ed. Panamericana; 2004.
37. Hartman, editor. Handbook of Osteopathic Technique. 3ª ed: Nelson Thornes; 2001.
38. Ramos C, Cataneo A, . Efeito do treinamento dos músculos respiratórios sobre a função pulmonar no preparo pré-operatório de tabagistas. *Acta Cirúrgica Brasileira*. 2007;22:98-104.
39. Moreno MA, Catai ,A M, Marcher, R, Amoroso, B L, de Castro, M, da Silva , E,. Effect of a muscle stretching program using the Global Postural Re-education method on respiratory muscle strength and thoracoabdominal mobility of sedentary young males. *J Bras Pneumol*. 2007;33 (6):679-86.
40. D'Angelo E, Prandi E, Marazzini L, Milic-Emili J. Dependence of maximal flow-volume curve on time course of preceding inspiration in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care*. 1994;150:1581-6.
41. Kano S, Burton DL, Lanteri CJ, Sly PD. Determination of peak expiratory flow. *Eur Respir J*. 1993;6:1347-52.
42. Krowka M, Enright PL, Rodarte JR, et al. Effect of effort on measurement of forced expiratory volume in one second. *Am Rev Respir Dis*. 1987;136:829-33.
43. Hegewald M, Lefor M, Jensen R, Crapo R, Kritchevsky S, Haggerty C, Bauer D, Satterfield S, Harris T. PEF is

- Not a Quality Indicator for Spirometry: PEF Variability and FEV1 are Poorly Correlated in an Elderly Population.* CHEST. 2007;149:4-9.
44. Boezen H, Schouten JP, Postma DS, Rijcken B. Distribution of peak expiratory flow variability by age, gender and smoking habits in a random population sample aged 20—70 yrs. *Eur Respir J*. 1994;7:1814-20.
45. Boezen M, Schouten J, Rijcken B, Vonk J, Gerritsen J, van der Zee S, Hoek G, Brunekreef B, Postma D. Peak Expiratory Flow Variability, Bronchial Responsiveness, and Susceptibility to Ambient Air Pollution in Adults. *Am J Respir Crit Care*. 1998;158:1848-56.
46. Brand P, Postma DS, Kerstjens HAM, Köeter GH, and the Dutch CNSLD Study Group. Relationship of airways hyperresponsiveness to respiratory symptoms and diurnal peak flow variation in patients with obstructive lung disease. *Am Rev Respir Dis*. 1991;143:916-21.
47. Ryan G, Latimer KM, Dolovich J, Hargreave FE. Bronchial responsiveness to histamine, relationship to diurnal variation of peak flow rate, improvement after bronchodilator, and airway calibre. *Thorax*. 1982;37:423-9.
48. Ramsdale E, Morris MM, Hargreave FE. Interpretation of the variability of peak flow rates in chronic bronchitis. *Thorax*. 1986;41:771-6.
49. Trigg C, Bennett JB, Tooley M, Sibbald B, D'Souza MF, Davies RJ. A general practice based survey of bronchial hyperresponsiveness and its relation to symptoms, sex, age, atopy, and smoking. *Thorax*. 1990;45:866-72.
50. Krljeza J, Lemmens T. 7th Revision of the declaration of Helsinki: Good news for the Transparency of Clinical Trials. *Croat Med J* 2009;50:105-10.

ISSN on line: 2173-9242

© 2012 – Eur J Ost Clin Rel Res - All rights reserved

www.europeanjournalosteopathy.com

info@europeanjournalosteopathy.com